Course for Interventionists in Training 2016

This was a ProEducar iniciative that was a Pre-Congress activity and took place on June 7th of 2016.

 

 

More articles by this author

See the Presentations of the 13th ProEducar Fellows Course

  During SOLACI-SBHCI 2023, our traditional education program for young interventionists ProEducar Fellows Course was held.  Discover the presentations of the prestigious interventionists that made part of this 13th edition...

The best images of the 13th ProEducar Fellows Course at SOLACI-SBHCI 2023

Relive the best images of the 13th ProEducar Fellows Course held on August 2 during the SOLACI-SBHCI 2023 Congress in the URCA Room of...

13th ProEducar-SOLACI Fellows Course Held at SOLACI-SBHCI 2023

ProEducar-SOLACI Fellows Course continues to grow! For the thirteenth consecutive year, the traditional SOLACI course for fellow interventionists was held at SOLACI-SBHCI 2023. The course...

Teve lugar o 13º Curso de Fellows do ProEducar-SOLACI no Congresso SOLACI-SBHCI 2023

o Curso de Fellows do ProEducar-SOLACI continua crescendo! Pelo décimo terceiro ano consecutivo teve lugar o tradicional Curso da SOLACI para intervencionistas em formação...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...